712 related articles for article (PubMed ID: 17698131)
21. Percentage of cancer in prostate biopsies as prognostic factor for staging and postoperative biochemical failure after radical prostatectomy.
Villamón-Fort R; Martínez-Jabaloyas JM; Soriano-Sarriá P; Ramos-Soler D; Pastor-Hernández F; Gil-Salom M
Urol Int; 2007; 78(4):328-33. PubMed ID: 17495491
[TBL] [Abstract][Full Text] [Related]
22. Sextant prostate biopsies predict side and sextant site of extracapsular extension of prostate cancer.
Elliott SP; Shinohara K; Logan SL; Carroll PR
J Urol; 2002 Jul; 168(1):105-9. PubMed ID: 12050501
[TBL] [Abstract][Full Text] [Related]
23. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.
Sengupta S; Blute ML; Bagniewski SM; Inman B; Leibovich BC; Slezak JM; Myers RP; Zincke H
BJU Int; 2008 Jan; 101(2):170-4. PubMed ID: 18173824
[TBL] [Abstract][Full Text] [Related]
24. PSA in the new millennium: a powerful predictor of prostate cancer prognosis and radical prostatectomy outcomes--results from the SEARCH database.
Freedland SJ; Hotaling JM; Fitzsimons NJ; Presti JC; Kane CJ; Terris MK; Aronson WJ; Amling CL
Eur Urol; 2008 Apr; 53(4):758-64; discussion 765-6. PubMed ID: 17868976
[TBL] [Abstract][Full Text] [Related]
25. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy.
Sengupta S; Myers RP; Slezak JM; Bergstralh EJ; Zincke H; Blute ML
J Urol; 2005 Dec; 174(6):2191-6. PubMed ID: 16280762
[TBL] [Abstract][Full Text] [Related]
26. Relating biopsy and clinical variables to radical prostatectomy findings: can insignificant and advanced prostate cancer be predicted in a screening population?
Anast JW; Andriole GL; Bismar TA; Yan Y; Humphrey PA
Urology; 2004 Sep; 64(3):544-50. PubMed ID: 15351590
[TBL] [Abstract][Full Text] [Related]
27. Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy.
Polascik TJ; Mayes JM; Sun L; Madden JF; Moul JW; Mouraviev V
Prostate; 2008 Sep; 68(13):1380-6. PubMed ID: 18543281
[TBL] [Abstract][Full Text] [Related]
28. Comparison of digital rectal examination and biopsy results with the radical prostatectomy specimen.
Obek C; Louis P; Civantos F; Soloway MS
J Urol; 1999 Feb; 161(2):494-8; discussion 498-9. PubMed ID: 9915434
[TBL] [Abstract][Full Text] [Related]
29. Factors predicting prostatic biopsy Gleason sum under grading.
Stackhouse DA; Sun L; Schroeck FR; Jayachandran J; Caire AA; Acholo CO; Robertson CN; Albala DM; Polascik TJ; Donatucci CF; Maloney KE; Moul JW
J Urol; 2009 Jul; 182(1):118-22; discussion 123-4. PubMed ID: 19447436
[TBL] [Abstract][Full Text] [Related]
30. The independent impact of extended pattern biopsy on prostate cancer stage migration.
Master VA; Chi T; Simko JP; Weinberg V; Carroll PR
J Urol; 2005 Nov; 174(5):1789-93; discussion 1793. PubMed ID: 16217288
[TBL] [Abstract][Full Text] [Related]
31. Is biopsy Gleason score independently associated with biochemical progression following radical prostatectomy after adjusting for pathological Gleason score?
Fitzsimons NJ; Presti JC; Kane CJ; Terris MK; Aronson WJ; Amling CL; Freedland SJ
J Urol; 2006 Dec; 176(6 Pt 1):2453-8; discussion 2458. PubMed ID: 17085127
[TBL] [Abstract][Full Text] [Related]
32. Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy.
Magheli A; Rais-Bahrami S; Carter HB; Peck HJ; Epstein JI; Gonzalgo ML
J Urol; 2007 Oct; 178(4 Pt 1):1277-80; discussion 1280-1. PubMed ID: 17698121
[TBL] [Abstract][Full Text] [Related]
33. Is there a difference in outcome after radical prostatectomy between patients with biopsy Gleason sums 4, 5, and 6? Results from the SEARCH database.
Freedland SJ; Amling CL; Terris MK; Presti JC; Aronson WJ; Elashoff D; Kane CJ;
Prostate Cancer Prostatic Dis; 2003; 6(3):261-5. PubMed ID: 12970733
[TBL] [Abstract][Full Text] [Related]
34. Obesity and risk of biochemical progression following radical prostatectomy at a tertiary care referral center.
Freedland SJ; Grubb KA; Yiu SK; Humphreys EB; Nielsen ME; Mangold LA; Isaacs WB; Partin AW
J Urol; 2005 Sep; 174(3):919-22. PubMed ID: 16093988
[TBL] [Abstract][Full Text] [Related]
35. The prognostic role of the pathological T2 subclassification for prostate cancer in the 2002 Tumour-Nodes-Metastasis staging system.
van Oort IM; Witjes JA; Kok DE; Kiemeney LA; Hulsbergen-Van De Kaa CA
BJU Int; 2008 Aug; 102(4):438-41. PubMed ID: 18336608
[TBL] [Abstract][Full Text] [Related]
36. Percentages of positive cores, cancer length and Gleason grade 4/5 cancer in systematic sextant biopsy are all predictive of adverse pathology and biochemical failure after radical prostatectomy.
Suekane S; Noguchi M; Nakashima O; Yamada S; Kojiro M; Matsuoka K
Int J Urol; 2007 Aug; 14(8):713-8. PubMed ID: 17681061
[TBL] [Abstract][Full Text] [Related]
37. Prostate biopsy clinical and pathological variables that predict significant grading changes in patients with intermediate and high grade prostate cancer.
Moussa AS; Li J; Soriano M; Klein EA; Dong F; Jones JS
BJU Int; 2009 Jan; 103(1):43-8. PubMed ID: 18782303
[TBL] [Abstract][Full Text] [Related]
38. Impact of patient age on biochemical recurrence rates following radical prostatectomy.
Magheli A; Rais-Bahrami S; Humphreys EB; Peck HJ; Trock BJ; Gonzalgo ML
J Urol; 2007 Nov; 178(5):1933-7; discussion 1937-8. PubMed ID: 17868723
[TBL] [Abstract][Full Text] [Related]
39. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods.
Yossepowitch O; Eggener SE; Bianco FJ; Carver BS; Serio A; Scardino PT; Eastham JA
J Urol; 2007 Aug; 178(2):493-9; discussion 499. PubMed ID: 17561152
[TBL] [Abstract][Full Text] [Related]
40. Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors.
Jack GS; Cookson MS; Coffey CS; Vader V; Roberts RL; Chang SS; Smith JA; Shappell SB
J Urol; 2002 Aug; 168(2):519-24. PubMed ID: 12131301
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
